- Home
- WHWK vs RLMD Comparison
WHWK vs RLMD Comparison
Compare WHWK & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- RLMD
- Stock Information
- Founded
- WHWK 2007
- RLMD 2004
- Country
- WHWK United States
- RLMD United States
- Employees
- WHWK N/A
- RLMD N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- WHWK Health Care
- RLMD Health Care
- Exchange
- WHWK Nasdaq
- RLMD Nasdaq
- Market Cap
- WHWK 95.2M
- RLMD 81.3M
- IPO Year
- WHWK N/A
- RLMD N/A
- Fundamental
- Price
- WHWK $2.20
- RLMD $3.31
- Analyst Decision
- WHWK
- RLMD Hold
- Analyst Count
- WHWK 0
- RLMD 2
- Target Price
- WHWK N/A
- RLMD $1.00
- AVG Volume (30 Days)
- WHWK 5.2M
- RLMD 1.5M
- Earning Date
- WHWK 11-06-2025
- RLMD 11-13-2025
- Dividend Yield
- WHWK N/A
- RLMD N/A
- EPS Growth
- WHWK N/A
- RLMD N/A
- EPS
- WHWK N/A
- RLMD N/A
- Revenue
- WHWK $14,384,000.00
- RLMD N/A
- Revenue This Year
- WHWK N/A
- RLMD N/A
- Revenue Next Year
- WHWK N/A
- RLMD N/A
- P/E Ratio
- WHWK N/A
- RLMD N/A
- Revenue Growth
- WHWK N/A
- RLMD N/A
- 52 Week Low
- WHWK $1.39
- RLMD $0.24
- 52 Week High
- WHWK $3.81
- RLMD $3.71
- Technical
- Relative Strength Index (RSI)
- WHWK 49.46
- RLMD 72.37
- Support Level
- WHWK $2.01
- RLMD $2.42
- Resistance Level
- WHWK $2.30
- RLMD $2.86
- Average True Range (ATR)
- WHWK 0.18
- RLMD 0.31
- MACD
- WHWK -0.04
- RLMD 0.07
- Stochastic Oscillator
- WHWK 35.58
- RLMD 76.93
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.